Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intensified Bu/Cy conditioning with ruxolitinib, decitabine, and venetoclax for allogeneic HSCT in high-risk hematologic malignancies
ChiCTR2500109090Phase 2Recruiting
- Sponsor
- Chinese PLA General Hospital
- Start
- Sep 2025
- Modality
- Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ruxolitinib, decitabine, venetoclax, busulfan and cyclophosphamide in leukemia, myelodysplastic syndrome (MDS), chronic myelomonocytic leukemia (CMML) and 2 more, sponsored by Chinese PLA General Hospital. Primary endpoint: 1-year GVHD-free and relapse-free survival (GFRFS). Started Sep 2025; status: recruiting.
02
Drugs
03
Conditions
leukemiamyelodysplastic syndrome (MDS)chronic myelomonocytic leukemia (CMML)myeloproliferative disorder (MPD)myelodysplastic/myeloproliferative neoplasm (MDS/MPN)
Beyond the preview
Go deeper on ChiCTR2500109090.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500109090.